Lima Feldmann João Felipe, Lima Feldmann João Henrique, Hidalgo-Filho Cassio Murilo, de Almeida Robatto Amanda Acioli, Araújo Breno Jeha, Viana Publio Cesar Cavalcante, de Castro Junior Gilberto
Clinical Oncology Department, Hospital Sírio-Libanês, São Paulo, SP 01308-050, Brazil.
https://orcid.org/0009-0005-6435-1349.
Ecancermedicalscience. 2025 Jul 17;19:1947. doi: 10.3332/ecancer.2025.1947. eCollection 2025.
Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.
We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.
The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.
The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.
晚期喉癌（LC）预后较差，治疗选择有限。处理寡转移具有挑战性，目前尚无标准推荐。
我们报告了一例64岁男性局部晚期LC患者，在基于顺铂的同步放化疗21个月后出现骨和肝寡转移疾病。最初，由于程序性死亡受体配体1（PD-L1）表达阴性，患者接受多西他赛、顺铂和西妥昔单抗联合治疗。化疗10个月后，活检证实肝脏出现新的进展。鉴于肝硬化肝脏中无症状的单部位进展，进行了微波消融。在2个月和4个月时，对孤立的骨转移灶进行了立体定向体部放射治疗，并用纳武单抗替代了西妥昔单抗。
患者22个月来无疾病进展迹象，耐受性良好。
纳武单抗与局部治疗之间的协同作用在处理喉癌寡转移方面似乎很有前景。
